Nganou-Makamdop K., Billingsley J.M., Yaffe Z., O’Connor G., Tharp G.K., Ransier A., Laboune F., Matus-Nicodemos R., Lerner A., Gharu L., Robertson J.M., Ford M.L., Schlapschy M., Kuhn N., Lensch A., Lifson J., Nason M., Skerra A., Schreiber G., Bosinger S.E., Douek D.C. (2018) Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication. PLoS Pathog. 14, e1007246.

⇒ Abstract

Hoffmann K., Milech N., Juraja S.M., Cunningham P.T., Stone S.R., Francis R.W., Anastasas M., Hall C.M., Heinrich T., Bogdawa H.M., Winslow S., Scobie M.N., Dewhurst R.E., Florez L., Ong F., Kerfoot M., Champain D., Adams A.M., Fletcher S., Viola H.M., Hool L.C., Connor T., Longville B.A.C., Tan Y.F., Kroeger K., Morath V., Weiss G.A., Skerra A., Hopkins R.M., Watt P.M. (2018) A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery. Sci. Rep. 8, 12538.

⇒ Abstract

Friedrich L., Kornberger P., Mendler C.T., Multhoff G., Schwaiger M., Skerra A. (2018) Selection of an Anticalin^® against the membrane form of Hsp70 via bacterial surface display and its theranostic application in tumour models. Biol. Chem. 14, 235-252.

⇒ Abstract

Ahmadpour S., Hosseinimehr S. J. (2018) PASylation as a powerful technology for improving the pharmacokinetic properties of biopharmaceuticals. Curr. Drug Deliv. 15, 331-341.

⇒ Abstract

Khodabakhsh F., Norouzian D., Vaziri B., Ahangari Cohan R., Sardari S., Mahboudi F., Behdani M., Mansouri K., Mehdizadeh A. (2017) Molecular design, expression and evaluation of Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties. Artif. Cells Nanomed. Biotechnol. 22, 39.

⇒ Abstract

Zvonova E. A., Ershov A. V., Ershova O.A., Sudomoina M. A., Degterev M. B., Poroshin G. N., Eremeev A. V., Karpov A. P., Vishnevsky A. Y., Goldenkova-Pavlova I. V., Petrov A. V., Ruchko S. V., Shuster A. M. (2017) PASylation technology improves recombinant interferon-β1b solubility, stability, and biological activity. Appl. Microbiol. Biotechnol. 101, 1975-1987.

⇒ Abstract

Hedayati M. H., Norouzian D., Aminian M., Teimourian S., Ahangari Cohan R., Sardari S., Khorramizadeh M. R. (2017) Molecular design, expression and evaluation of PASylated human recombinant erythropoietin with enhanced functional properties. Protein J. 36, 36-48.

⇒ Abstract

Harder M. J., Kuhn N., Schrezenmeier H., Höchsmann B., von Zabern I., Weinstock C., Simmet T., Ricklin D., Lambris J. D., Skerra A., Anliker M., Schmidt C. Q. (2016) Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood 129, 970-980.

⇒ Abstract

Zelikin A.N., Ehrhardt C. and Healy A.M. (2016) Materials and methods for delivery of biological drugs. Nat. Chem. 8, 997-1007.

⇒ Abstract

Lerchner A., Daake M., Jarasch A., Skerra A. (2016) Fusion of an alcohol dehydrogenase with an aminotransferase using a PAS linker to improve coupled enzymatic alcohol-to-amine conversion. Protein Eng. Des. Sel. 29, 557-562.

⇒ Abstract

Mendler C. T., Feuchtinger A., Heid I., Aichler M., D’Alessandria C., Pirsig S., Blechert B., Wester H. J., Braren R., Walch A., Skerra A., Schwaiger M. (2016) Tumor uptake of anti-CD20 Fabs depends on tumor perfusion. J. Nucl. Med. 57, 1971-1977.

⇒ Abstract

Chhabra K. H., Adams J. M., Jones G. L. , Yamashita M., Schlapschy M., Skerra A., Rubinstein M. and Low M. J. (2016) Reprogramming the body weight set point by a reciprocal interaction of hypothalamic leptin sensitivity and Pomc gene expression reverts extreme obesity.
Mol. Metab. 5, 869–881.

⇒ Abstract

Bolze F., Bast A., Mocek S., Morath V., Yuan D., Rink N., Schlapschy M., Zimmermann A., Heikenwalder M., Skerra A., Klingenspor M. (2016) Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation. Diabetologia 59, 2005-2012.

⇒ Abstract

Fracasso G., Falvo E., Colotti G., Fazi F., Ingegnere T., Amalfitano A., Doglietto G.B., Alfieri S., Boffi A., Morea V., Conti G., Tremante E., Giacomini P., Arcovito A., Ceci P. (2016) Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness. J. Control. Release 239, 10-18.

⇒ Abstract

Falvo E., Tremante E., Arcovito A., Papi M., Elad N., Boffi A., Morea V., Conti G., Toffoli G., Fracasso G., Giacomini P., Ceci P. (2016) Improved doxorubicin encapsulation and pharmacokinetics of ferritin-fusion protein nanocarriers bearing proline, serine, and alanine elements. Biomacromolecules 17, 514-522.

⇒ Abstract

Mendler C. T., Gehring T., Schwaiger M., Wester H.J., Skerra A. (2015) 89^Zr-labeled versus 124^I-labeled αHER2 Fab with optimized plasma half-life for high-contrast tumor imaging in vivo. J. Nucl. Med. 56, 1112-1118.

⇒ Abstract